Investors Buy Large Volume of Compass Therapeutics Put Options (NASDAQ:CMPX)

Compass Therapeutics, Inc. (NASDAQ:CMPX) was the target of some unusual options trading on Tuesday. Investors purchased 22,702 put options on the stock. This is an increase of approximately 797% compared to the average volume of 2,532 put options.

Hedge Funds Weigh In On Compass Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Tower Research Capital LLC TRC lifted its stake in Compass Therapeutics by 298.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company’s stock valued at $25,000 after acquiring an additional 12,917 shares during the period. Independent Advisor Alliance acquired a new position in Compass Therapeutics during the fourth quarter valued at $26,000. BNP Paribas Financial Markets purchased a new stake in Compass Therapeutics in the fourth quarter valued at $27,000. Intech Investment Management LLC acquired a new stake in Compass Therapeutics during the 3rd quarter worth about $30,000. Finally, Mariner LLC acquired a new stake in Compass Therapeutics during the 4th quarter worth about $30,000. Institutional investors and hedge funds own 68.43% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on CMPX shares. Guggenheim started coverage on Compass Therapeutics in a research report on Monday, February 24th. They issued a “buy” rating and a $12.00 price target for the company. Jefferies Financial Group increased their price target on shares of Compass Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Monday, February 10th. Piper Sandler started coverage on shares of Compass Therapeutics in a research report on Wednesday, February 19th. They issued an “overweight” rating and a $12.00 price objective on the stock. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Compass Therapeutics in a research report on Wednesday, January 8th. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $32.00 price target on shares of Compass Therapeutics in a report on Tuesday. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $11.38.

Compass Therapeutics Stock Up 12.4 %

Shares of CMPX traded up $0.24 during trading hours on Tuesday, reaching $2.14. 15,018,770 shares of the company traded hands, compared to its average volume of 751,988. The business has a fifty day moving average price of $2.84 and a 200-day moving average price of $2.10. Compass Therapeutics has a 12-month low of $0.77 and a 12-month high of $4.08. The stock has a market capitalization of $295.23 million, a P/E ratio of -5.79 and a beta of 1.19.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01). As a group, research analysts predict that Compass Therapeutics will post -0.36 EPS for the current fiscal year.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.